Findings

What do systematic reviews say?

14 questions · 14 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 12 · 85.7%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 14.3%Moderate 0 · 0%High 0 · 0%

Low‐dose angiotensin receptor blockers (ARB) vs high‐dose ARB

Death (all causes) · people with diabetes and kidney disease

1 finding from 1 review

Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic… 2024 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 156 participants
Low

Low‐dose angiotensin receptor blockers (ARB) vs high‐dose ARB

Cardiovascular mortality · people with diabetes and kidney disease

1 finding from 1 review

Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic… 2024 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 156 participants
Low

Low‐dose angiotensin receptor blockers (ARB) vs high‐dose ARB

Doubling of SCr · people with diabetes and kidney disease

The review found no eligible studies for this question.

1 finding from 1 review

Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic… 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low‐dose angiotensin receptor blockers (ARB) vs high‐dose ARB

Fatal or nonfatal stroke · people with diabetes and kidney disease

The review found no eligible studies for this question.

1 finding from 1 review

Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic… 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low‐dose angiotensin receptor blockers (ARB) vs high‐dose ARB

Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease

The review found no eligible studies for this question.

1 finding from 1 review

Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic… 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low‐dose angiotensin receptor blockers (ARB) vs high‐dose ARB

Micro‐ to macroalbuminuria · people with diabetes and kidney disease

The review found no eligible studies for this question.

1 finding from 1 review

Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic… 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low‐dose angiotensin receptor blockers (ARB) vs high‐dose ARB

Micro‐ to normoalbuminuria · people with diabetes and kidney disease

The review found no eligible studies for this question.

1 finding from 1 review

Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic… 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low‐dose angiotensin receptor blockers (ARB) plus spironolactone vs high‐dose ARB plus spironolactone

All‐cause death · people with diabetes and kidney disease

The review found no eligible studies for this question.

1 finding from 1 review

Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic… 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low‐dose angiotensin receptor blockers (ARB) plus spironolactone vs high‐dose ARB plus spironolactone

Cardiovascular mortality · people with diabetes and kidney disease

The review found no eligible studies for this question.

1 finding from 1 review

Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic… 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low‐dose angiotensin receptor blockers (ARB) plus spironolactone vs high‐dose ARB plus spironolactone

Doubling of SCr · people with diabetes and kidney disease

The review found no eligible studies for this question.

1 finding from 1 review

Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic… 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low‐dose angiotensin receptor blockers (ARB) plus spironolactone vs high‐dose ARB plus spironolactone

Fatal or nonfatal stroke · people with diabetes and kidney disease

The review found no eligible studies for this question.

1 finding from 1 review

Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic… 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low‐dose angiotensin receptor blockers (ARB) plus spironolactone vs high‐dose ARB plus spironolactone

Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease

The review found no eligible studies for this question.

1 finding from 1 review

Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic… 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low‐dose angiotensin receptor blockers (ARB) plus spironolactone vs high‐dose ARB plus spironolactone

Micro‐ to macroalbuminuria · people with diabetes and kidney disease

The review found no eligible studies for this question.

1 finding from 1 review

Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic… 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Low‐dose angiotensin receptor blockers (ARB) plus spironolactone vs high‐dose ARB plus spironolactone

Micro‐ to normoalbuminuria · people with diabetes and kidney disease

The review found no eligible studies for this question.

1 finding from 1 review

Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic… 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found